(3,4-dimethylphenoxy)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3,4-dimethylphenoxy)acetamide
• 英文别名: 2-(3,4-dimethylphenoxy)acetamide
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD01034445
• 分子量: 179.219
• InChiKey: YVZZAPKKUOBYDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3,4-dimethylphenoxy)acetamide 、 Lithium aluminium hydride 、 水 、 sodium hydroxide 、 以 四氢呋喃 为溶剂， 反应 5.0h， 以to obtain 0.63 g (yield 28%) of the title compound as a colorless oil的产率得到[2-(3,4-二甲基苯氧基)乙基]胺盐酸盐
  参考文献：
  名称：

  Phenylacetamide derivatives

  摘要：

  式(I)中的苯乙酰胺衍生物具有强效的镇痛和抗炎活性，并且表现出较少的刺激性和毒性：##STR1## 其中，X、Y、W、n、m和Ar的定义如规范中所述。

  公开号：

  US05973201A1
• 作为产物：
  描述：

  3,4-二甲基苯氧基乙酸 在 ammonium hydroxide 、 氯化亚砜 作用下， 以 二氯甲烷 、 2-(3,4-二甲氧基苯氧基)乙酸 为溶剂， 以80%的产率得到(3,4-dimethylphenoxy)acetamide
  参考文献：
  名称：

  Phenylacetamide derivatives

  摘要：

  式(I)的苯乙酰胺衍生物具有强效的镇痛和抗炎活性，并且表现出较少的刺激性和毒性：##STR1## 其中，X、Y、W、n、m和Ar如规范中定义的那样。

  公开号：

  US05973201A1

文献信息

• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193034A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾病和症状的化合物、组合物和方法。
• Synthesis and Biological Evaluation of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors
  作者：Wei Shen、Shian Yu、Jiaming Zhang、Weizheng Jia、Qing Zhu

  DOI：10.3390/molecules191118620

  日期：——

  Monoamine oxidases (EC 1.4.3.4; MAOs), a family of FAD-containing enzymes, is an important target for antidepressant drugs. In this paper, a series of 2-phenoxyacetamide analogues were synthesized, and their inhibitory potency towards monoamine oxidases A (MAO-A) and B (MAO-B) were evaluated using enzyme and cancer cell lysate. 2-(4-Methoxyphenoxy)acetamide (compound 12) (SI = 245) and (2-(4-((prop-2-ynylimino)methyl)phenoxy)acetamide (compound 21) (IC50MAO-A = 0.018 μM, IC50MAO-B = 0.07 μM) were successfully identified as the most specific MAO-A inhibitor, and the most potent MAO-A/-B inhibitor, respectively. The inhibitory activities of these two compounds in living cells were also further evaluated utilizing HepG2 and SHSY-5Y cell lysates.

  单胺氧化酶（EC 1.4.3.4；MAOs）是一类含有FAD的酶，是抗抑郁药物的重要靶点。本文中，合成了一系列2-苯氧乙酰胺类似物，并使用酶和癌细胞裂解液评估了它们对单胺氧化酶A（MAO-A）和B（MAO-B）的抑制活性。成功鉴定出2-（4-甲氧基苯氧基）乙酰胺（化合物12）（SI = 245）和2-（4-（（丙-2-炔基亚氨基）甲基）苯氧基）乙酰胺（化合物21）（IC50MAO-A = 0.018 μM，IC50MAO-B = 0.07 μM）分别作为最特异的MAO-A抑制剂和最强的MAO-A/-B抑制剂。还利用HepG2和SHSY-5Y细胞裂解液进一步评估了这两种化合物在活细胞中的抑制活性。
• Proteasome inhibitors and methods of using the same
  申请人：Bernadini Raffaella

  公开号：US20050107307A1

  公开（公告）日：2005-05-19

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以通过抑制蛋白酶体活性等方式调节细胞凋亡。这些化合物和组合物可以用于诱导细胞凋亡并治疗癌症等疾病，以及与蛋白酶体活性直接或间接相关的其他疾病。
• Novel quinazoline derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20070010671A1

  公开（公告）日：2007-01-11

  The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(1)，并作为MCH受体拮抗剂。这些化合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴食障碍（包括贪食症、厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆）、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。
• PROTEASOME INHIBITORS AND METHODS OF USING THE SAME
  申请人：Bernardini Raffaella

  公开号：US20090291918A1

  公开（公告）日：2009-11-26

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节细胞凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导细胞凋亡和治疗癌症及其他与蛋白酶体活性直接或间接相关的疾病。